TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: change in tear film break up area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiological assessment of OA of the knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported function (HAQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sensitivity of the ultrasound exam with Doppler
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the ultrasound exam with Doppler
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of US image acquisition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for dexamethasone insert
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preference for topical prednisolone insert
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 2-log reduction in RSV load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of oral symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of definite IS episodes
Endpoint domain: Adverse events/effects
Primary endpoint: PICC-tip placement accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean proportion of days that step per day goals were attained
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence rate of CNS infections
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of current Impulse Control Disorder (ICD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with Adverse Events (AEs) due to AZD5817
Endpoint domain: Adverse events/effects
Primary endpoint: Self-efficacy regarding HIV risk reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Injection risk behavior reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Regional tissue oxygenation saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight gain (g/d)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Vaso-Occlusive Crisis Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vq-derm questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: DLQI quality of life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: global blood oxygen level-dependent (BOLD) response to hypercapnia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat mass and lean body mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial perfusion and glucose uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ovulation Confirmation by Progesterone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life: Infertility quality of life questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Antigen-specific Immune Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Kinetics of Mycobacterial-specific Immune Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Amino acid absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mTORC1 pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Endocrine markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Functionality of laryngeal pacemaker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Continuation of use
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: PK profiles of SRA-444
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference from baseline in Left Ventricular End-Systolic Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Grade III plus IV Neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Gustilo type of the open fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean Difference in Stroke Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: urinary bacterial and viral microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Peripheral vascular imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Composite of intra- and postoperative in hospital all-cause mortality and serious cardiac events
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of Diabetic Macular Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Streptococcus mutans count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Joint position accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction of patients susceptible to develop AKI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: One minute sit-to-stand test (1-min STST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worsening of heart failure (HF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hospitalization due to worsening of heart failure (HF)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: serum a-GST relative to baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to osteoporosis treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Risk of prevalent type 2 diabetes mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Grade ≥3 local and systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Observed Plasma Concentration of S-888711
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Observed Plasma Concentration of S-888711
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve from Time Zero to Infinity of S-888711
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of steps walking ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in eating behaviors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in coronary calcium score (CAC score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Therapeutic window boundaries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of prospective screening for ovarian cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normal ranges and distributions of CA 125
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in Sleep Duration
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Impact on Psychological Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Impact on Overall Health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Platelet mitochondrial respiratory chain enzyme activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Follow up completion rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Up-regulation of airway regulatory T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Peak plasma concentration (Cmax) of tiotropium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUC) of tiotropium from time zero to 72 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Truncated area under the concentration-time curve (AUC) of tiotropium from time zero to 30 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of eyes obtaining 20/40 or better distance best corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence/severity of adverse events and complications
Endpoint domain: Adverse events/effects
Primary endpoint: Complete Pain Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fractional exhaled nitric oxide (FeNO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: impulse oscillometry (IOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of hip migration (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of scoliosis (Cobb angle)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Participants Achieving an Improvement of at Least 0.22 Units in HAQ
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Change From Baseline in SF-36 Physical Component Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Change From Baseline in SF-36 Mental Component Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Distant metastases free survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in Impact on Participation and Autonomy Questionnaire-Autonomy Outdoors Sub scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in Impact on Participation and Autonomy Questionnaire- Social Life and Relationships Sub scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in Self report of feelings of isolation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: percentage of patients with neurological improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Consistency of HRMAS NMR spectroscopy results with histological analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total pulmonary resistance (TPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of patients transfused after one month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of bone-implant interface
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum Tolerated Dose (Induction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (Consolidation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pyloric wall thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Thrombotic Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage days abstinent from any substance use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Asynchrony rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Diary Sleep Efficiency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Frequency of grade 3 or higher treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the curve from time zero to the time of the last quantifiable plasma concentration (AUC0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak concentration at each treatment period (Cmax,tp)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure levels at home after getting up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Upper urinary tract infection and systemic inflammatory response syndrome (SIRS)
Endpoint domain: Adverse events/effects
Primary endpoint: severity of postoperative nausea and vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Cerebral oxygen saturation changes (rSO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Peripheral muscle blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in basal C-peptide level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Composite score from Hamilton Anxiety Rating Scale (HAM-A) and Hamilton Rating Scale for Depression (HAM-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in MAT (MASCC Antiemesis Tool) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Any Dose-limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with adverse drug reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in LSAS total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in 24-hour Urine Protein to Creatinine Ratio (UPCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Activity minutes using Activity tracker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calories Burnt using Activity Tracker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Heart rate and Heart rate variability using Activity Tracker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complications at surgery using Clavien-Dindo Classification
Endpoint domain: Adverse events/effects
Primary endpoint: Parental comfort level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in vegetable and nutrient consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Modified Asworth Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: STREAM and PASS scales
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Presence of T2DM or T1DM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Event Free Survival (ESF)
Endpoint domain: Mortality/survival
Primary endpoint: Sputum Neutrophil Percentages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fistula Formation
Endpoint domain: Adverse events/effects
Primary endpoint: Increased immune activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Effectiveness of the ELMO system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of vitamin D supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: α1-adrenoceptor Vasoreactivity With L-NMMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: α1-adrenoceptor Vasoreactivity With Endogenous ADMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety as evaluated by adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum drug serum concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum serum concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of severe blood pressure drops
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Investigator's Global Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment engagement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Remission from MDD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Posit Science Double Decision Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average thickness of signal-rich area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximum scan penetrance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: signal intensities under the fibrous cap
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical physiological response to cocaine challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with an anastomotic leak
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of patients receiving early discontinuation of EAT
Endpoint domain: Adverse events/effects
Primary endpoint: Virological treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Freedom from device SADEs
Endpoint domain: Adverse events/effects
Primary endpoint: Serious procedure related SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Constant Work Rate (CWR) Exercise Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Experienced a Relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Sputum Bacillary Loads: Adjusted Area Under the Curve (aAUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Sputum Bacillary Loads: Early Bactericidal Activity (EBA) Days 0 to 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extended Early Bactericidal Activity (EBA) From Days 2 to 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: observed toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Change in momentary craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in momentary pain: numeric rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year Local Recurrence (LR)
Endpoint domain: Mortality/survival
Primary endpoint: preferred vaccine formulation, dosage, and schedule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 18F-Dopa influx constant (Ki)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Profile of volatile organic compounds of the breath
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standardized uptake value of 177Lu-DOTA-EB-TATE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Early Viral Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Toxin Neutralizing Antibody (TNA) Level at Day 63
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Acute glycemic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acute systolic blood pressure effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disability-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of participants who report ever having had a CRC screening test
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Subjects With ≥2-Grade Improvement in Facial Wrinkle Scale Ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who receive 131 I-MIBG
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 50% decrease in HDRS-17 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absorption of EPA and DHA in the plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bioavailability of EPA and DHA in the plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Needle image accuracy score difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery Time Post-Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4-year Progression-Free Survival (4y-PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Viral detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Vertebral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Trabecular Bone Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean defect in Octopus perimetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Half-life time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative wound healing change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes